Steve Rose
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- COVID-19 Clinical Research Studies 10
-
- Cardiac Arrest and Resuscitation 3
- Journals
- JAMA (8 papers)Nature (4 papers)Intensive Care Medicine (4 papers)The Lancet (3 papers)Intensive Care Medicine Experimental (1 paper)
- Partner nations
- United KingdomAustraliaVietnam
In The Last Decade
Steve Rose
28 papers receiving 3.2k citations
Steve Rose's Hit Papers
Peers
Comparison fields: 5 of 113
- Infectious Diseases 1.6k
- Applied Microbiology and Biotechnology 42
- Genetics 507
- Internal Medicine 45
- Pulmonary and Respiratory Medicine 373
Countries citing papers authored by Steve Rose
This map shows the geographic impact of Steve Rose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Rose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Rose more than expected).
Fields of papers citing papers by Steve Rose
This network shows the impact of papers produced by Steve Rose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Rose. The network helps show where Steve Rose may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 5 | 2021 | 213 | |
| 6 | 2021 | 166 | |
| 7 | 2016 | 145 | |
| 8 | 2021 | 142 | |
| 9 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 10 | 2017 | 112 | |
| 11 | 2022 | 105 | |
| 12 | 2022 | 100 | |
| 13 | Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis Hit paper breakdown → | 2024 | 94 |
| 14 | 2021 | 72 | |
| 15 | 2023 | 62 | |
| 16 | 2023 | 60 | |
| 17 | 2022 | 54 | |
| 18 | 2023 | 46 | |
| 19 | 2022 | 45 | |
| 20 | 2021 | 37 |
About Steve Rose
Steve Rose is a scholar working on Infectious Diseases, Emergency Medicine, Genetics, Epidemiology and Pulmonary and Respiratory Medicine, having authored 29 papers that have together received 3.3k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (10 papers), Genetic Associations and Epidemiology (6 papers), Sepsis Diagnosis and Treatment (5 papers), Cardiac Arrest and Resuscitation (3 papers), Respiratory Support and Mechanisms (3 papers), Antibiotics Pharmacokinetics and Efficacy (1 paper), Global Health and Surgery (1 paper) and Vitamin C and Antioxidants Research (1 paper). The work is most often cited by research in Infectious Diseases (1.6k citations), Applied Microbiology and Biotechnology (42 citations), Genetics (507 citations), Internal Medicine (45 citations) and Pulmonary and Respiratory Medicine (373 citations). Steve Rose has collaborated with scholars based in United Kingdom, Australia and Vietnam. Their work appears in journals such as JAMA, Nature, Intensive Care Medicine, The Lancet and Intensive Care Medicine Experimental.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.